secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-227505
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy designation for TSHA-102 in Rett syndrome; pivotal trial protocol finalized
--------------------------------------------------------------------------------

- FDA Breakthrough Therapy designation for TSHA-102 based on Part A data from 12 patients showing 100% response rate on milestone gain.
- FDA alignment finalized on REVEAL pivotal trial protocol and SAP; 6-month interim analysis could expedite BLA by at least two quarters.
- Pivotal trial to enroll 15 females aged 6-22 with primary endpoint of milestone gain; enrollment on track for Q4 2025.
- Clinical data also showed dose-dependent improvements on R-MBA and CGI-I; safety generally well-tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525227505/0001193125-25-227505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525227505/d61846d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-227505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer